The sera of HIV-infected individuals often do not show evidence of neutralization, either against laboratory strains of the virus or their homotypic isolate. Instead, these sera frequently enhance HIV infection in several cell types including human lymphocytes, macrophages and fibroblasts. The antibodies which are responsible for this phenomenon could play a role in increasing the spread of HIV in the host and the eventual destruction of immune cells. Antibody-dependent enhancement (ADE) of HIV seems to proceed independent of the CD4 receptor, and this process in macrophages appears to be mediated by the Fc receptor. However, the mechanism for enhancement in other cell types has not been defined, and the particular epitope(s) of HIV proteins involved in enhancement have not been identified. The objectives of this research proposal are to define the mechanisms by which HIV infect CD4+ lymphocytes and fibroblasts through serum enhancement, to identify the viral proteins involved in the ADE process and to determine the relative role of complement and Fc receptors in this process. The importance of ADE in the progression to AIDS will also be evaluated. Finally, the possible involvement of ADE in bringing about superinfection of HIV- infected cells and generation of recombinant virus will be examined. The information gained from these studies should be critical for the development of a safe and effective HIV vaccine, and could be helpful for approaches aimed at limiting HIV spread in vivo.
Eaton, A M; Ugen, K E; Weiner, D B et al. (1994) An anti-gp41 human monoclonal antibody that enhances HIV-1 infection in the absence of complement. AIDS Res Hum Retroviruses 10:13-8 |
Levy, J A (1993) HIV pathogenesis and long-term survival. AIDS 7:1401-10 |
Kliks, S C; Shioda, T; Haigwood, N L et al. (1993) V3 variability can influence the ability of an antibody to neutralize or enhance infection by diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 90:11518-22 |
Werner, A; Levy, J A (1993) Human immunodeficiency virus type 1 envelope gp120 is cleaved after incubation with recombinant soluble CD4. J Virol 67:2566-74 |